Nashville Biosciences and Datavant announced a collaboration that will enable biopharma companies to connect their trial data to research datasets from BioVU®. The linkages will accelerate drug discovery, clinical development, and drug safety activities.
Nashville Biosciences helps life sciences companies answer questions related to drug discovery and health outcomes research by analyzing approximately 3.5 million de-identified electronic medical records, including a subset of approximately 275,000 records that are linked to DNA samples collected under an Institutional Review Board (IRB)-approved process over the past 15 years.
Datavant will extend these capabilities by enabling life sciences clients to compliantly de-identify and connect their clinical trial and registry data to Nashville Biosciences’ rich clinical, genomic, and imaging datasets.
“We are proud of the rich insights we’ve been able to provide to biopharma companies seeking new druggable targets or striving to understand the natural history of diseases and patient outcomes,” said Leeland Ekstrom, Co-founder, and Chief Executive Officer. “Working with Datavant, we’ll be able to go a step further by enabling the creation of even richer datasets to drive innovation all along the biopharma R&D pipeline.”
“Clinico-genomic datasets are key to unlocking discoveries of new drug targets and improving outcomes research,” said Travis May, Founder, and President of Datavant. “Securely connecting this type of highly nuanced data with data from clinical trials will help unlock a step-change in the speed at which new therapies will be discovered and successfully brought to market.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!